The success rate of induction therapy for myeloma can vary depending on the drug combination used, individual health factors, and how "success" is defined. Generally, success is measured by how deeply the myeloma responds — ideally reaching what's called a "complete response," where no cancer cells are detectable by Show Full Answer
The success rate of induction therapy for myeloma can vary depending on the drug combination used, individual health factors, and how "success" is defined. Generally, success is measured by how deeply the myeloma responds — ideally reaching what's called a "complete response," where no cancer cells are detectable by standard tests.
The main goal of induction therapy is to achieve a deep remission as quickly as possible. Here's what success can look like:
- Complete response (CR): No myeloma cells detected in blood or bone marrow tests
- Stringent complete response (sCR): An even deeper level of remission, confirmed by more sensitive testing
- Partial response: A significant reduction in myeloma cells, even if not fully undetectable
The most commonly used induction regimen — daratumumab, lenalidomide, bortezomib, and dexamethasone (also called Dara-RVd) — has shown strong results, with many people achieving deep remission. It's worth noting that success rates can also depend on whether a stem cell transplant follows induction therapy. Adding daratumumab to standard induction combinations has helped more people with newly diagnosed myeloma achieve no detectable cancer cells, even for those who aren't eligible for a transplant.
Talking with a healthcare team is the best way to understand what success might look like for a specific situation, as treatment plans are highly personalized.
July 28
Join
Your Privacy Choices
